Abstract
Original language | Undefined/Unknown |
---|---|
Pages (from-to) | 216-231 |
Number of pages | 16 |
Journal | International Archives of Allergy and Immunology |
Volume | 158 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2012 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Severe Chronic Allergic (and Related) Diseases: A Uniform Approach - A MeDALL - GA(2)LEN - ARIA Position Paper. / Bousquet, J; Anto, JM; Demoly, P et al.
In: International Archives of Allergy and Immunology, Vol. 158, No. 3, 2012, p. 216-231.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Severe Chronic Allergic (and Related) Diseases: A Uniform Approach - A MeDALL - GA(2)LEN - ARIA Position Paper
AU - Bousquet, J
AU - Anto, JM
AU - Demoly, P
AU - Schunemann, HJ
AU - Togias, A
AU - Akdis, M
AU - Auffray, C
AU - Bachert, C
AU - Bieber, T
AU - Bousquet, PJ
AU - Carlsen, KH
AU - Casale, TB
AU - Cruz, AA
AU - Keil, T
AU - Carlsen, KCL
AU - Maurer, M
AU - Ohta, K
AU - Papadopoulos, NG
AU - Rodriguez, MR
AU - Samolinski, B
AU - Agache, I
AU - Andrianarisoa, A
AU - Ang, CS
AU - Annesi-Maesano, I
AU - Ballester, F
AU - Baena-Cagnani, CE
AU - Basagana, X
AU - Bateman, ED
AU - Bel, EH
AU - Bedbrook, A
AU - Beghe, B
AU - Beji, M
AU - Ben Kheder, A
AU - Benet, M
AU - Bennoor, KS
AU - Bergmann, KC
AU - Berrissoul, F
AU - Jensen, CB
AU - Bleecker, ER
AU - Bonini, S
AU - Boner, AL
AU - Boulet, LP
AU - Brightling, CE
AU - Brozek, JL
AU - Bush, A
AU - Busse, WW
AU - Camargos, PAM
AU - Canonica, GW
AU - Carr, W
AU - Cesario, A
AU - Chen, YZ
AU - Chiriac, AM
AU - Costa, DJ
AU - Cox, L
AU - Custovic, A
AU - Dahl, R
AU - Darsow, U
AU - Didi, T
AU - Dolen, WK
AU - Douagui, H
AU - Dubakiene, R
AU - El-Meziane, A
AU - Fonseca, JA
AU - Fokkens, WJ
AU - Fthenou, E
AU - Gamkrelidze, A
AU - Garcia-Aymerich, J
AU - Gerth van Wijk, Roy
AU - Gimeno-Santos, E
AU - Guerra, S
AU - Haahtela, T
AU - Haddad, H
AU - Hellings, PW
AU - Hellquist-Dahl, B
AU - Hohmann, C
AU - Howarth, P
AU - Hourihane, JO
AU - Humbert, M
AU - Jacquemin, B
AU - Just, J
AU - Kalayci, O
AU - Kaliner, MA
AU - Kauffmann, F
AU - Kerkhof, M
AU - Khayat, G
AU - N'Goran, BK
AU - Kogevinas, M
AU - Koppelman, GH
AU - Kowalski, ML
AU - Kull, I
AU - Kuna, P
AU - Larenas, D
AU - Lavi, I
AU - Le, LT
AU - Lieberman, P
AU - Lipworth, B
AU - Mahboub, B
AU - Makela, MJ
AU - Martin, F
AU - Martinez, FD
AU - Marshall, GD
AU - Mazon, A
AU - Melen, E
AU - Meltzer, EO
AU - Mihaltan, F
AU - Mohammad, Y
AU - Mohammadi, A
AU - Momas, I
AU - Morais-Almeida, M
AU - Mullol, J
AU - Muraro, A
AU - Naclerio, R
AU - Nafti, S
AU - Namazova-Baranova, L
AU - Nawijn, MC (Martijn)
AU - Nyembue, TD
AU - Oddie, S
AU - O'Hehir, RE
AU - Okamoto, Y
AU - Orru, MP
AU - Ozdemir, C
AU - Ouedraogo, GS
AU - Palkonen, S
AU - Panzner, P
AU - Passalacqua, G
AU - Pawankar, R
AU - Pigearias, B
AU - Pin, I
AU - Pinart, M
AU - Pison, C
AU - Popov, TA
AU - Porta, D
AU - Postma, DS
AU - Price, D
AU - Rabe, KF
AU - Ratomaharo, J
AU - Reitamo, S
AU - Rezagui, D
AU - Ring, J
AU - Roberts, R
AU - Roca, J
AU - Rogala, B
AU - Romano, A
AU - Rosado-Pinto, J
AU - Ryan, D
AU - Sanchez-Borges, M
AU - Scadding, GK
AU - Sheikh, A (Aziz)
AU - Simons, FER
AU - Siroux, V
AU - Schmid-Grendelmeier, PD
AU - Smit, HA
AU - Sooronbaev, T
AU - Stein, RT
AU - Sterk, PJ
AU - Sunyer, J
AU - Terreehorst, I
AU - Toskala, E
AU - Tremblay, Y
AU - Valenta, R
AU - Valeyre, D
AU - Vandenplas, O
AU - van Weel, C
AU - Vassilaki, M
AU - Varraso, R
AU - Viegi, G
AU - Wang, DY
AU - Wickman, M
AU - Williams, D
AU - Wohrl, S
AU - Wright, J
AU - Yorgancioglu, A
AU - Yusuf, OM
AU - Zar, HJ
AU - Zernotti, ME
AU - Zidarn, M
AU - Zhong, N
AU - Zuberbier, T
PY - 2012
Y1 - 2012
N2 - Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies. Copyright (C) 2012 S. Karger AG, Basel
AB - Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies. Copyright (C) 2012 S. Karger AG, Basel
U2 - 10.1159/000332924
DO - 10.1159/000332924
M3 - Article
VL - 158
SP - 216
EP - 231
JO - International Archives of Allergy and Immunology
JF - International Archives of Allergy and Immunology
SN - 1018-2438
IS - 3
ER -